首页> 外国专利> Paclitaxel-Hyaluronic Acid Conjugate in the Treatment of Non-Muscle Invasive Bladder Cancer

Paclitaxel-Hyaluronic Acid Conjugate in the Treatment of Non-Muscle Invasive Bladder Cancer

机译:紫杉醇 - 透明质酸缀合物治疗非肌肉侵袭性膀胱癌

摘要

For use in the treatment of non-muscle invasive bladder cancer (NMIBC) by intravesical instillation following a once-weekly dose of 600 mg per week or a twice-weekly dose equivalent to a total of 1,200 mg per week for 12 weeks or 6 consecutive weeks of treatment A pharmaceutical composition consisting essentially of a paclitaxel prodrug in association with a pharmaceutically acceptable diluent/excipient is described. The paclitaxel prodrug used was prepared by introducing a spacer (4-bromobutyric acid) between the hyaluronic acid and the chemotherapeutic agent according to the indirect synthesis process between the hyaluronic acid (HA) molecule and the paclitaxel molecule.
机译:用于通过膀胱内滴注治疗非肌肉侵袭性膀胱癌(NMIBC),在每周600毫克的每周600毫克或两次相当于每周每周1,200毫克的两次,连续12周或6次治疗数周处理的药物组合物基本上与药学上可接受的稀释剂/赋形剂相关联的紫杉醇前药组成。通过根据透明质酸(HA)分子和紫杉醇分子之间的间接合成过程在透明质酸和化学治疗剂之间引入间隔物(4-溴丁酸)来制备使用的紫杉醇前药。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号